Exhibit 10.44


 


PORTIONS
OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED


SEPARATELY
WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN


APPLICATION
FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE


SECURITIES
EXCHANGE ACT OF 1934; [***] DENOTES OMISSIONS


 


Memorandum
Of Understandings


 


This
memorandum of understanding (this “MOU”) is entered this January 8, 2018 and is intended to reflect our mutual
agreement concerning the contemplated assignment of distribution rights and a license from Resdevco Research and Development Ltd.
(Private Company 510422223, hereinafter “Resdevco”) to Wize Pharma Ltd. of Hanagr 5b Hod Hasharon, Israel (“Wize”).


 


In
this document the following terms will have the meaning corresponding to them as follows:


 


“Product”
shall mean Resdevco’s LO2A unit dose Eye Drops and all indications relating thereto, as described in Appendix C of the Agreement.


 


“Current
Territories” shall mean Switzerland, Germany, Holland, Israel, Ukraine and the USA.


 


“Additional
Territories” shall mean all territories other than Current Territories, excluding the People’s Republic of China


 


“Net
Sales” shall mean the income actually received by Wize from sales of the Product from the first fully independent market
organization in a sales chain to consumers, less commissions paid (by Wize) to third parties in connection with the production
and sale of the Product.


 


The
business understandings which we have reached are as follows:


 


		1.	Worldwide
                                         License 



 


		1.1	The
                                         existing license agreement between the parties, including without limitation that certain
                                         Exclusive Distribution and Licensing Agreement dated May 1, 2015 between the parties
                                         attached hereto as Appendix A (the “License Agreement”) shall continue to
                                         be in full force and effect, and its continuing effect shall be a condition precedent
                                         to the effect of the undertakings in this MOU, and to the continuing effect of all agreements
                                         entered thereunder.



 


		1.2	Resdevco
                                         will grant Wize an exclusive license to sell and distribute the Product in Additional
                                         Territories - in return for royalties as set forth in Appendix B enclosed hereto for
                                         the Term of this Agreement. The license set forth herein shall not cover Current Territories
                                         (“License”).



 






    	 	1	 



     


    

 


		1.3	The
                                         License granted to Wize shall be conditioned, in each Additional Territory, on reaching
                                         minimum sales targets within the time frame stipulated for each such Additional Territory,
                                         in a specific license agreement which will need to be signed per each new Additional
                                         Territory, based on the general terms and conditions set forth herein, and as setforth
                                         in Appendix B enclosed hereto.



 


		1.4	In
                                         every Additional Territory in which the Products shall be sold - Resdevco shall be entitled
                                         to a minimum per Product as per the formula detailed in APPENDIX B, payable jointly and
                                         severally from Wize and the distributor appointed by it, and the agreement with each
                                         distributor, agent, or reseller of whatever form or structure, in each Additional Territory
                                         - shall require Resdevco’s prior written approval for above said territory. Subject to
                                         compliance with obligations stipulated in Appendix B, Resdevco’s prior written
                                         approval shall not be unreasonably withheld.



 


		1.5	The
                                         License hereunder will be granted for 5 years, and shall be automatically renewed for
                                         each additional term of 5 years, subject to full compliance with the terms herein, and
                                         the continuing effect of the License Agreement.



 


		1.6	[***]



 


		1.7	[***]



 


		1.8	Regardless
                                         of the party that initiated or finalized the deal with the distributor, Wize will be
                                         responsible for overseeing the registration process and enabling the relationship between
                                         the distributor and the Manufacturer in a timely manner and Wize shall use best efforts
                                         to enable the distribution of the Product



 


[***]


 


The
existing engagements of distributors in Current Territories shall continue to be in place, and shall continue to be managed by
Resdevco. The Parties will act to maintain business continuity in the Current Territories.


 


The
License Agreement shall be assigned to Wize Pharma Ltd, and shall inure to the benefit of the parties hereof. The distribution
agreement between the parties for Israel, Ukraine and China shall remain in place.


 


Wize
may assign this agreement to a third party providing Resdevco a written prior written notice and guaranteeing the compliance of
such assignee with the terms thereof. Such assignment shall require the prior written consent of Resdevco given in good faith,
and not to be unreasonably withheld.


 






    	 	2	 



     


    

 


		2.	Additional
                                         Terms and Conditions



 


The
term of this MOU is in effect until a definitive agreement is signed in respect of the subject matter hereof. The parties are
committed and will do their utmost effort to complete such a definitive agreement within three months.


 


If
Wize becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, files or has
filed against it a petition which is not reversed within 60 days of filing thereof, or institution of voluntary proceedings in
bankruptcy, liquidation, dismantling – all its rights under this MOU and all agreements entered subject thereto shall terminate
and be of no force and effect.


 


Resdevco
may freely assign and transfer its rights under this agreement or any of the agreements related therein to third parties.


 


Neither
Party hereto shall be liable for non-fulfillment of its obligations or for any failure or delay caused by force majeure, provided
such force majeure occurrence shall immediately be notified to the other party. So far as reasonable the activities held up by
force majeure shall be taken up as soon as adequately possible after the respective cause no longer prevails. In the event of
any delay resulting from such causes, the time for performance under this Agreement shall be extended on a day to day basis.


 


Except
as required by applicable law, none of the parties hereto (nor any of their respective affiliates, officers, directors, associates,
shareholders, advisors, agents or representatives) shall issue any press release or make any other public disclosure relating
to, or connected with, this letter or the matters contained herein (including, without limitation, the fact that this letter has
been executed or that the negotiations contemplated hereby have commenced) without obtaining the prior approval of the other party,
except for the disclosure by each of the parties hereto of this letter to its officers, directors and advisors on a need-to-know
basis provided such parties keep this letter and its content confidential, or as may be required under law, including without
limitation any regulated reporting requirements of Wize. Each party hereto agrees to maintain the confidentiality of this MOU
and the transactions contemplated hereby. This provision shall be binding on the parties, whether definitive agreements are entered
or not.


 






    	 	3	 



     


    

 


This
MOU shall be governed by, and construed in accordance with, the laws of the State of Israel, and without regard to its conflict
of law provisions. The place


of
any legal proceedings is Jerusalem, Israel


 


Any
legal action or proceeding with respect to any of the obligations arising under or relating to this MOU will be brought to the
competent courts in Jerusalem which shall have an exclusive jurisdiction in respect thereof.


 


No
reliance may be made on the agreement reflected herein by any person, including the parties hereof, and no liability or rescission
or change in the terms hereof shall be assumed by either party.


 


Confirmed
and agreed as of the date first set forth above.


 


	 	Wize Pharma Ltd.	 	Resdevco Ltd.
	 	 	 	 	 	 
	 	By	/s/
Or Eisenberg	 	By	/s/ Prof. S. Dikstein
	 	 	Name:
    Or Eisenberg	 	 	Name:
    Prof. S. Dikstein
	 	 	Title:
    CFO & Acting CEO	 	 	Title:
    CEO


 






    	 	4	 



     


    

 


Appendix
A


 


Commitments
by Wize Pharma


 


Wize
is committed to completing two double-blind clinical trials, according to a Protocol prepared under the supervision of Wize and
applicable Ethics Committee (IRB) Approvals and other regulatory approvals, as may be required. The duration of the clinical trial
will be dependent on the number of participants recruited. Wize shall extend best efforts to recruit the required number of patients
in the designated timeframe, but if recruitment is low, the parties will extend the time frame for completion of the clinical
trials accordingly.


 


The
first will test the efficacy of the Product for treating Conjunctivochalasis


 


The
Second will test the efficacy of the Product for treating Sjogren’s Syndrome Dry Eyes


 


Both
the above clinical trials should be completed by [***].


 


Wize
is committed to complete the Pre-IND process vis a vis the FDA for the the indications: “treating Conjunctivochalasis”
and/or the indication “treating Sjogren’s Syndrome Dry Eyes”, as per regulatory specialist recommendations,
and receive the said recommendations and plan by [***]





 






    	 	5	 



     


    

 


Appendix
B


 


The
royalties for sales in Additional Territories and in the USA will be the higher of $[***] or [***]% from Net Sales for the duration
of the local distribution agreement signed separately with each local distributor.


  


Minimum
annual sales target formula is [***].


 


If
it is less than $[***] per year, then the minimum sales target is prorated by the GDP.


 


[***]


 






    	 	6	 



     


    

 




Appendix
C


 


PRODUCT
description and formula


 


1.
Unit dose or any other future dose or packaging eye drops to treat dry eye and/or Conjunctivochalasis currently sold in Hungary
as Conheal® (in Germany as Hylan®) The product is currently manufactured by PharmaStulln GmbH in Germany and by Excel
Vision in France currently sold in Switzerland as Lacrycon®. In the future, the Product may be produced by another contract
manufacturer approved by Resdevco.


 


3.
The expenses involving the box design for the Territory are paid by LICENSEE.


 


4.
As far as RESDEVCO knows the ex factory= ex works price of Conheal® (containing 2x5x3 =30 unit dose) is [***] euro.


 


 


7